

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6436211

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECOND LIEN SECURITY INTEREST IN PATENTS
CONVEYING PARTY DATA	
Name	Execution Date
ROYAL BANK OF CANADA, AS COLLATERAL AGENT	12/07/2020
RECEIVING PARTY DATA	
Name:	AVISTA PHARMA SOLUTIONS, INC.
Street Address:	3501 TRICENTER BLVD., SUITE C
City:	DURHAM
State/Country:	NORTH CAROLINA
Postal Code:	27713
PROPERTY NUMBERS Total: 33	
Property Type	Number
Patent Number:	9981978
Patent Number:	9981979
Patent Number:	10370382
Application Number:	62339136
Application Number:	15036335
Application Number:	15211062
Application Number:	62359719
Application Number:	62491337
Application Number:	15477343
Application Number:	15603556
Application Number:	14995547
Application Number:	62587132
Application Number:	15849834
Application Number:	62686299
Application Number:	16100315
Application Number:	62755679
Application Number:	16192103
Application Number:	16123251
Application Number:	16302944
Application Number:	16315778

PATENT

Property Type	Number
Application Number:	62798735
Application Number:	62798738
Application Number:	16263518
Application Number:	16420627
Application Number:	62292653
Application Number:	62160188
Application Number:	12466457
Application Number:	10429420
Application Number:	10166236
Application Number:	12445771
Application Number:	12612089
Application Number:	13378176
Application Number:	12973453

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2123186532
Email: alanagramer@paulhastings.com
Correspondent Name: ALANA GRAMER
Address Line 1: 200 PARK AVENUE
Address Line 2: C/O PAUL HASTINGS LLP
Address Line 4: NEW YORK, NEW YORK 10166

NAME OF SUBMITTER:	ALANA GRAMER
SIGNATURE:	/s/ Alana Gramer
DATE SIGNED:	12/07/2020

Total Attachments: 5

source=Cambrex (Amendment No.1) - Second Lien Patent Security Release (Executed)(152364810_1)#page1.tif
source=Cambrex (Amendment No.1) - Second Lien Patent Security Release (Executed)(152364810_1)#page2.tif
source=Cambrex (Amendment No.1) - Second Lien Patent Security Release (Executed)(152364810_1)#page3.tif
source=Cambrex (Amendment No.1) - Second Lien Patent Security Release (Executed)(152364810_1)#page4.tif
source=Cambrex (Amendment No.1) - Second Lien Patent Security Release (Executed)(152364810_1)#page5.tif

RELEASE OF SECOND LIEN SECURITY INTEREST IN PATENTS

This **RELEASE OF SECOND LIEN SECURITY INTEREST IN PATENTS** (this "Release") is made as of December 7, 2020 (the "Effective Date") by Royal Bank of Canada, as collateral agent for the Secured Parties (in such capacity, the "Collateral Agent") in favor of Cambrex Charles City, Inc. and Avista Pharma Solutions, Inc. (collectively, the "Grantors"). Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Second Lien Pledge and Security Agreement (as defined below) and (to the extent not defined therein) the Second Lien Credit Agreement.

WHEREAS, the Grantors, specified affiliates of Grantors and the Collateral Agent have entered into that certain Second Lien Pledge and Security Agreement dated as of December 4, 2019 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Second Lien Pledge and Security Agreement");

WHEREAS, pursuant to the Second Lien Pledge and Security Agreement, the Grantors and the Collateral Agent entered into that certain Second Lien Patent Security Agreement dated December 4, 2019 (the "Second Lien Patent Security Agreement"), which was recorded with the United States Patent and Trademark Office on December 4, 2019, at Reel 051196, Frame 0080;

WHEREAS, pursuant to the Second Lien Pledge and Security Agreement and the Second Lien Patent Security Agreement, each Grantor granted to the Collateral Agent, for the benefit of the Secured Parties, a continuing security interest in all of such Grantor's right, title and interest in, to and under all of the following, whether then owned or thereafter acquired by such Grantor and wherever located (collectively, the "Patent Collateral"): (i) all Patents (as defined below) of such Grantor, including, without limitation, the issued and applied-for Patents of such Grantor listed on Schedule I hereto and (ii) all Proceeds and Products of the foregoing (excluding any Excluded Property); and

WHEREAS, each Grantor has satisfied the terms of the Second Lien Pledge and Security Agreement and requests, and the Collateral Agent has agreed to grant, a release of such continuing security interest and Lien granted and recorded against the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby, on behalf of itself and the Secured Parties, agrees as follows:

SECTION 1. Defined Terms. For purposes of this Release, the term "Patents" shall mean, with respect to any Person and throughout the world, all of the following now owned or hereafter acquired by such Person: (a) all patents, patent applications and similar registrations, including registrations and applications in the United States Patent and Trademark Office (or any similar office in any other country) and including, in the case of any Grantor, those Patents set forth next to its name on Schedule I hereto and (b) all reissues, continuations, divisions, continuations-in-part, renewals or extensions thereof, all inventions


claimed therein and patentable improvements thereto, including the right to make, use or sell the inventions claimed therein or patentable improvements thereto.

SECTION 2. Release of Security Interest in Patent Collateral. The Collateral Agent hereby (i) terminates the Second Lien Patent Security Agreement and releases any and all Liens and security interests in the Patent Collateral and re-assigns to each Grantor any and all right, title and interest it may have in, to and under the Patent Collateral; (ii) agrees that, at the applicable Grantor's expense, it shall execute and deliver all other documents and do all other acts necessary or that a Grantor may reasonably request to relinquish, and effect or evidence such termination and the release of, such rights to the Grantors; and (iii) authorizes and requests that the United States Patent and Trademark Office note and record the release hereby given and any other filings necessary to evidence the release and termination of the Collateral Agent's rights under the Second Lien Pledge and Security Agreement with respect to the Patent Collateral.

SECTION 3. GOVERNING LAW. **THIS RELEASE AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS RELEASE OR THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed, on behalf of itself and the Secured Parties, by its duly authorized representative effective as of the Effective Date.

ROYAL BANK OF CANADA, as Collateral
Agent

By: 
Name: Ann Hurley
Title: Manager, Agency

SCHEDULE I

Patent Registrations and Applications

Title	App. No.	Filing Date	Patent No.	Issue Date	Owner
PREPARATION OF SATURATED KETONE MORPHINAN COMPOUNDS BY CATALYTIC ISOMERISATION	14/906,776	01-21-2016	9,981,978	05-29-2018	Cambrex Charles City, Inc.
PROCESS FOR THE FORMATION OF HYDROCODONE BITATRATE	15/523,054	04-28-2017	9,981,979	05-29-2018	Cambrex Charles City, Inc.
NEW PROCESS FOR PREPARING HYDROMORPHONE AND DERIVATIVES THEREOF	15/747,980	01-26-2018	10,370,382	08-06-2019	Cambrex Charles City, Inc.
SYNTHETIC PROCESS AND NOVEL INTERMEDIATES	62/339,136	05-20-2016			Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	15/036,335	05-12-2016	9,643,963	05-09-2017	Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	15/211,062	07-15-2016	9,686,991	06-27-2017	Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	62/359,719	07-08-2016			Avista Pharma Solutions, Inc.
Synthetic Process and Novel Intermediates	62/491,337	04-28-2017			Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	15/477,343	04-03-2017			Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	15/603,556	05-24-2017	9,883,674	02-06-2018	Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	14/995,547	01-14-2016	9,420,793	08-23-2016	Avista Pharma Solutions
SINGLE ENANTIOMER ANTIPARASITIC COMPOUNDS	62/587,132	11-16-2017			Avista Pharma Solutions, Inc.
ANTIPARASITIC COMPOUNDS	15/849,834	12-21-2017	10,092,001	10-09-2018	Avista Pharma Solutions, Inc.
Chemical Compounds	62/686,299	06-18-2018			Avista Pharma Solutions, Inc.
A COMPOUND 1-[2-[4-(2-ETHYL-6,8-DIMETHYLIMIDAZO[1,2-a]PYRAZIN-3-YL)PHENYL]ETHYL]-3-(p-TOLYLSULFONYL)UREA AS A PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST	16/100,315	08-10-2018	10,239,885	03-26-2019	Avista Pharma Solutions, Inc.
Chemical Compounds	62/755,679	11-05-2018			Avista Pharma Solutions, Inc.
SINGLE ENANTIOMER ANTIPARASITIC COMPOUNDS	16/192,103	11-15-2018			Avista Pharma Solutions, Inc.
Antiparasitic Compounds	16/123,251	09-06-2018	10,342,234	07-09-2019	Avista Pharma Solutions, Inc.

Title	App. No.	Filing Date	Patent No.	Issue Date	Owner
Synthetic Process and Novel Intermediates	16/302,944	11-19-2018			Avista Pharma Solutions, Inc.
Antiparasitic Compounds	16/315,778	01-07-2019			Avista Pharma Solutions, Inc.
Synthetic Process and Novel Intermediates	62/798,735	01-30-2019			Avista Pharma Solutions, Inc.
Chemical Compounds	62/798,738	01-30-2019			Avista Pharma Solutions, Inc.
Chemical Compounds	16/263,518	01-31-2019			Avista Pharma Solutions, Inc.
Antiparasitic Compounds	16/420,627	05-23-2019			Avista Pharma Solutions, Inc.
MODEL FOR SCREENING DRUGS FOR THE TREATMENT OF HEARTWORM DISEASE	62/292,653	02-08-2016			Avista Pharma Solutions, Inc.
Antiparasitic Compounds	62/160,188	05-12-2015			Avista Pharma Solutions, Inc.
METHOD OF MAKING AMPHETAMINE	12/466,457	05-15-2009	7,705,184	04-27-2010	Cambrex Charles City, Inc.
NICOTINE-CONTAINING, CONTROLLED RELEASE COMPOSITION AND METHOD	10/429,420	05-05-2003	6,828,336	12-07-2004	Cambrex Charles City, Inc.
NICOTINE-CONTAINING, CONTROLLED RELEASE COMPOSITION AND METHOD	10/166,236	05-28-2002	6,586,449	07-01-2003	Cambrex Charles City, Inc.
PROCESS FOR PREPARING ANHYDROUS ARIPIRAZOLE TYPE I	12/445,771	04-16-2009	8,039,621	10-18-2011	Cambrex Charles City, Inc.
METHOD OF MAKING PIPERIDINE DERIVATIVES	12/612,089	11-04-2009	8,299,258	10-30-2012	Cambrex Charles City
METHODS AND COMPOSITIONS FOR PREPARATION OF AMPHETAMINE CONJUGATES AND SALTS THEREOF	13/378,176	02-15-2012	8,614,346	12-24-2013	Cambrex Charles City, Inc.
Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof	12/973,453	12-20-2010	8,779,191	07-15-2014	Cambrex Charles City, Inc.

1285206-NYCSR01A - MSW
LEGAL_US_E # 152257305.3